JP2018502138A - Map4k4(hgk)インヒビター - Google Patents
Map4k4(hgk)インヒビター Download PDFInfo
- Publication number
- JP2018502138A JP2018502138A JP2017537944A JP2017537944A JP2018502138A JP 2018502138 A JP2018502138 A JP 2018502138A JP 2017537944 A JP2017537944 A JP 2017537944A JP 2017537944 A JP2017537944 A JP 2017537944A JP 2018502138 A JP2018502138 A JP 2018502138A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- indol
- phenylsulfonyl
- etoac
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 15
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 title abstract description 8
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 150000004678 hydrides Chemical class 0.000 claims abstract description 16
- 206010027476 Metastases Diseases 0.000 claims abstract description 12
- 230000009401 metastasis Effects 0.000 claims abstract description 12
- 230000004565 tumor cell growth Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000009467 reduction Effects 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 150000005215 alkyl ethers Chemical class 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 150000003973 alkyl amines Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- VSPBWOAEHQDXRD-UHFFFAOYSA-N 1h-indole-6-carbaldehyde Chemical compound O=CC1=CC=C2C=CNC2=C1 VSPBWOAEHQDXRD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 11
- 101710144518 Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 410
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 328
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 241
- 239000000243 solution Substances 0.000 description 235
- 235000019439 ethyl acetate Nutrition 0.000 description 205
- 239000011541 reaction mixture Substances 0.000 description 133
- -1 Cyanoyanyl Chemical group 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 229910004298 SiO 2 Inorganic materials 0.000 description 57
- 239000007787 solid Substances 0.000 description 54
- 238000004587 chromatography analysis Methods 0.000 description 47
- 239000012267 brine Substances 0.000 description 46
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- 239000000284 extract Substances 0.000 description 44
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 41
- 238000003818 flash chromatography Methods 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 34
- 229910052739 hydrogen Inorganic materials 0.000 description 32
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 32
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 32
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 28
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 26
- 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 24
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 description 24
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 23
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000010992 reflux Methods 0.000 description 17
- 206010060862 Prostate cancer Diseases 0.000 description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 15
- 239000006185 dispersion Substances 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- LAGWFKSQVPRITG-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-methoxyindole Chemical compound C1=CC2=CC(OC)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 LAGWFKSQVPRITG-UHFFFAOYSA-N 0.000 description 13
- 125000004404 heteroalkyl group Chemical group 0.000 description 13
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 229960003668 docetaxel Drugs 0.000 description 11
- ADZUEEUKBYCSEY-UHFFFAOYSA-N 1h-indole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC=CC2=C1 ADZUEEUKBYCSEY-UHFFFAOYSA-N 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- VQYKEEGYJVMFFD-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-methoxyindole-2-carbaldehyde Chemical compound O=CC1=CC2=CC(OC)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 VQYKEEGYJVMFFD-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- LQORWTDKWNXPCY-UHFFFAOYSA-N 1-(benzenesulfonyl)indole-5-carbaldehyde Chemical compound C1=CC2=CC(C=O)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 LQORWTDKWNXPCY-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000027311 M phase Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 6
- VEPTXBCIDSFGBF-UHFFFAOYSA-M tetrabutylazanium;fluoride;trihydrate Chemical compound O.O.O.[F-].CCCC[N+](CCCC)(CCCC)CCCC VEPTXBCIDSFGBF-UHFFFAOYSA-M 0.000 description 6
- UDMYZUCHWKDAOC-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-methylindazole-5-carbaldehyde Chemical compound CC1=NN(C2=CC=C(C=C12)C=O)S(=O)(=O)C1=CC=CC=C1 UDMYZUCHWKDAOC-UHFFFAOYSA-N 0.000 description 5
- IHQRFMMXDRDENR-UHFFFAOYSA-N 1H-indol-5-yl-(5-methoxy-1H-indol-2-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC IHQRFMMXDRDENR-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- PMRKJJHKXZJLHG-UHFFFAOYSA-N (5-hydroxy-1H-indol-2-yl)-(3-methyl-1H-indol-5-yl)methanone Chemical compound OC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=CNC2=CC=1)C PMRKJJHKXZJLHG-UHFFFAOYSA-N 0.000 description 4
- UZNDQFMLONSZPA-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-methoxy-3-methylindole Chemical compound C1=C(C)C2=CC(OC)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 UZNDQFMLONSZPA-UHFFFAOYSA-N 0.000 description 4
- PXWGULPBKHJNDI-UHFFFAOYSA-N 1H-indazol-5-yl-(5-methoxy-1H-indol-2-yl)methanone Chemical compound N1N=CC2=CC(=CC=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC PXWGULPBKHJNDI-UHFFFAOYSA-N 0.000 description 4
- XDJNHYAQZWCIAH-UHFFFAOYSA-N 5-bromo-3-methyl-2h-indazole Chemical compound C1=CC(Br)=CC2=C(C)NN=C21 XDJNHYAQZWCIAH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HMLBNAAXODMXTB-UHFFFAOYSA-N (3-chloro-1H-indol-5-yl)-(3,4-dichloro-5-methoxy-1H-indol-2-yl)methanone Chemical compound ClC1=CNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C(=C2C=1Cl)Cl)OC HMLBNAAXODMXTB-UHFFFAOYSA-N 0.000 description 3
- MCUCXDIBZGLENB-UHFFFAOYSA-N (3-chloro-1H-indol-5-yl)-(3-chloro-5-methoxy-1H-indol-2-yl)methanone Chemical compound ClC1=CNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1Cl)OC MCUCXDIBZGLENB-UHFFFAOYSA-N 0.000 description 3
- QIPQFMXWUZTZEH-UHFFFAOYSA-N (3-chloro-1H-indol-5-yl)-(5-methoxy-1H-indol-2-yl)methanone Chemical compound ClC1=CNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC QIPQFMXWUZTZEH-UHFFFAOYSA-N 0.000 description 3
- UMEKKRIANYHDAN-UHFFFAOYSA-N (3-chloro-2H-indazol-5-yl)-(5-methoxy-1H-indol-2-yl)methanone Chemical compound ClC1=NNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC UMEKKRIANYHDAN-UHFFFAOYSA-N 0.000 description 3
- BWNFQJAFANQDMQ-UHFFFAOYSA-N (3-chloro-5-methoxy-1H-indol-2-yl)-(3-methyl-1H-indol-5-yl)methanone Chemical compound ClC1=C(NC2=CC=C(C=C12)OC)C(=O)C=1C=C2C(=CNC2=CC=1)C BWNFQJAFANQDMQ-UHFFFAOYSA-N 0.000 description 3
- DRDIZNKSCTZDFS-UHFFFAOYSA-N (5-fluoro-1H-indol-2-yl)-(3-methyl-2H-indazol-5-yl)methanone Chemical compound FC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=NNC2=CC=1)C DRDIZNKSCTZDFS-UHFFFAOYSA-N 0.000 description 3
- VSRUZVGLXHNXSS-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-(3-methyl-1H-indol-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=CNC2=CC=1)C VSRUZVGLXHNXSS-UHFFFAOYSA-N 0.000 description 3
- ILQYAERLQHNXBH-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-[2-(trifluoromethyl)-3H-benzimidazol-5-yl]methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C1=CC2=C(NC(=N2)C(F)(F)F)C=C1 ILQYAERLQHNXBH-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VTTVLLNHPCCQKJ-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-methylindole-5-carbaldehyde Chemical compound CC1=CN(C2=CC=C(C=C12)C=O)S(=O)(=O)C1=CC=CC=C1 VTTVLLNHPCCQKJ-UHFFFAOYSA-N 0.000 description 3
- KEPQQULYWDIKEK-UHFFFAOYSA-N 1-(benzenesulfonyl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=CC=C1 KEPQQULYWDIKEK-UHFFFAOYSA-N 0.000 description 3
- SIPLGHRKGGTBOX-UHFFFAOYSA-N 1H-indol-6-yl-(5-methoxy-1H-indol-2-yl)methanone Chemical compound N1C=CC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC SIPLGHRKGGTBOX-UHFFFAOYSA-N 0.000 description 3
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- FVVKRVAVAMWVMM-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-chloroindol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound ClC1=CN(C2=CC=C(C=C12)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 FVVKRVAVAMWVMM-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- DWCJFCUFRDDECU-UHFFFAOYSA-N (3,4-dichloro-5-methoxy-1H-indol-2-yl)-(1H-indazol-5-yl)methanone Chemical compound ClC1=C(NC2=CC=C(C(=C12)Cl)OC)C(=O)C=1C=C2C=NNC2=CC=1 DWCJFCUFRDDECU-UHFFFAOYSA-N 0.000 description 2
- QLBGPTJYAVARQO-UHFFFAOYSA-N (3-chloro-5-methoxy-1H-indol-2-yl)-(1H-indazol-5-yl)methanone Chemical compound ClC1=C(NC2=CC=C(C=C12)OC)C(=O)C=1C=C2C=NNC2=CC=1 QLBGPTJYAVARQO-UHFFFAOYSA-N 0.000 description 2
- QEGLVSQQQVDGBY-UHFFFAOYSA-N (3-ethyl-2H-indazol-5-yl)-(5-methoxy-1H-indol-2-yl)methanone Chemical compound C(C)C1=NNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC QEGLVSQQQVDGBY-UHFFFAOYSA-N 0.000 description 2
- ZVGCXUGQXNNSNU-UHFFFAOYSA-N (3-fluoro-2H-indazol-5-yl)-(5-methoxy-1H-indol-2-yl)methanone Chemical compound FC1=NNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC ZVGCXUGQXNNSNU-UHFFFAOYSA-N 0.000 description 2
- PQAAIHDZDCSUNU-UHFFFAOYSA-N (3-methyl-2H-indazol-5-yl)-(4-phenylmethoxy-1H-indol-2-yl)methanone Chemical compound C(C1=CC=CC=C1)OC1=C2C=C(NC2=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C PQAAIHDZDCSUNU-UHFFFAOYSA-N 0.000 description 2
- BEAABHSMPGTGEA-UHFFFAOYSA-N (3-methyl-2H-indazol-5-yl)-(5-phenylmethoxy-1H-indol-2-yl)methanone Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=NNC2=CC=1)C BEAABHSMPGTGEA-UHFFFAOYSA-N 0.000 description 2
- LTYPPGSLKQLZBM-UHFFFAOYSA-N (4-chloro-5-methoxy-1H-indol-2-yl)-(1H-indazol-5-yl)methanone Chemical compound ClC1=C2C=C(NC2=CC=C1OC)C(=O)C=1C=C2C=NNC2=CC=1 LTYPPGSLKQLZBM-UHFFFAOYSA-N 0.000 description 2
- JRDLPHWSPRTGKW-UHFFFAOYSA-N (4-methoxy-1H-indol-2-yl)-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC1=C2C=C(NC2=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C JRDLPHWSPRTGKW-UHFFFAOYSA-N 0.000 description 2
- JHGBUGFKTDZZHM-UHFFFAOYSA-N (5,6-dimethoxy-1H-indol-2-yl)-(1H-indol-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1OC)C(=O)C=1C=C2C=CNC2=CC=1 JHGBUGFKTDZZHM-UHFFFAOYSA-N 0.000 description 2
- DAIRNLGBRSTQNY-UHFFFAOYSA-N (5,6-dimethoxy-1H-indol-2-yl)methanol Chemical compound COC=1C=C2C=C(NC2=CC=1OC)CO DAIRNLGBRSTQNY-UHFFFAOYSA-N 0.000 description 2
- XNLUFWPPENHWQP-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-(1-methylindol-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C=CN(C2=CC=1)C XNLUFWPPENHWQP-UHFFFAOYSA-N 0.000 description 2
- HKLRXZMQVFPJFA-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-(1H-pyrrolo[2,3-b]pyridin-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=NC=1)NC=C2 HKLRXZMQVFPJFA-UHFFFAOYSA-N 0.000 description 2
- BWOYQNYRPFQUIZ-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-(2-methyl-3H-benzimidazol-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C1=CC2=C(NC(=N2)C)C=C1 BWOYQNYRPFQUIZ-UHFFFAOYSA-N 0.000 description 2
- YJUUOMPSOVWMBA-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=NNC2=CC=1)C YJUUOMPSOVWMBA-UHFFFAOYSA-N 0.000 description 2
- NMZUMFICRMBSIG-UHFFFAOYSA-N (5-methoxy-1H-indol-2-yl)-[3-(morpholin-4-ylmethyl)-2H-indazol-5-yl]methanone Chemical compound COC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=NNC2=CC=1)CN1CCOCC1 NMZUMFICRMBSIG-UHFFFAOYSA-N 0.000 description 2
- AVROOOVBVGTXRX-UHFFFAOYSA-N (5-methoxy-1H-pyrrolo[2,3-c]pyridin-2-yl)-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC=1C=C2C(=CN=1)NC(=C2)C(=O)C=1C=C2C(=NNC2=CC=1)C AVROOOVBVGTXRX-UHFFFAOYSA-N 0.000 description 2
- XTIMLMXSXMCCBZ-UHFFFAOYSA-N (5-methoxy-3-methyl-1H-indol-2-yl)-(3-methyl-1H-indol-5-yl)methanone Chemical compound COC=1C=C2C(=C(NC2=CC=1)C(=O)C=1C=C2C(=CNC2=CC=1)C)C XTIMLMXSXMCCBZ-UHFFFAOYSA-N 0.000 description 2
- FWIKPEKWMZAEFN-UHFFFAOYSA-N (7-methoxy-1H-indol-2-yl)-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC=1C=CC=C2C=C(NC=12)C(=O)C=1C=C2C(=NNC2=CC=1)C FWIKPEKWMZAEFN-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- FSERHDPEOFYMMK-UHFFFAOYSA-N 1-(5-bromo-1h-indol-3-yl)-n,n-dimethylmethanamine Chemical compound C1=C(Br)C=C2C(CN(C)C)=CNC2=C1 FSERHDPEOFYMMK-UHFFFAOYSA-N 0.000 description 2
- ZTNPZJQLIBWJDY-UHFFFAOYSA-N 1-(5-bromo-2-fluorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC(Br)=CC=C1F ZTNPZJQLIBWJDY-UHFFFAOYSA-N 0.000 description 2
- YEGNCFBZBOGYBA-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-(trifluoromethyl)benzimidazole-5-carbaldehyde Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C(=NC2=C1C=CC(=C2)C=O)C(F)(F)F YEGNCFBZBOGYBA-UHFFFAOYSA-N 0.000 description 2
- MCUBHOYLUVGROH-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-chloroindazole-5-carbaldehyde Chemical compound ClC1=NN(C2=CC=C(C=C12)C=O)S(=O)(=O)C1=CC=CC=C1 MCUBHOYLUVGROH-UHFFFAOYSA-N 0.000 description 2
- GHPYPNVSPXHDOO-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-chloroindole-5-carbaldehyde Chemical compound ClC1=CN(C2=CC=C(C=C12)C=O)S(=O)(=O)C1=CC=CC=C1 GHPYPNVSPXHDOO-UHFFFAOYSA-N 0.000 description 2
- NOZQJJICOUNKBM-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-fluoroindazole-5-carbaldehyde Chemical compound FC1=NN(C2=CC=C(C=C12)C=O)S(=O)(=O)C1=CC=CC=C1 NOZQJJICOUNKBM-UHFFFAOYSA-N 0.000 description 2
- XVKWEQXYPUFFLU-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-chloro-5-methoxyindole-2-carbaldehyde Chemical compound ClC1=C2C=C(N(C2=CC=C1OC)S(=O)(=O)C1=CC=CC=C1)C=O XVKWEQXYPUFFLU-UHFFFAOYSA-N 0.000 description 2
- WFJZWPQCOUYAQU-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-methoxyindole Chemical compound C1=CC=2C(OC)=CC=CC=2N1S(=O)(=O)C1=CC=CC=C1 WFJZWPQCOUYAQU-UHFFFAOYSA-N 0.000 description 2
- PJQIKOUOYALITN-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-phenylmethoxyindole Chemical compound C1=CC2=C(OCC=3C=CC=CC=3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 PJQIKOUOYALITN-UHFFFAOYSA-N 0.000 description 2
- GHSTYTIZXKAYQC-UHFFFAOYSA-N 1-(benzenesulfonyl)-5,6-dimethoxyindole-2-carbaldehyde Chemical compound COC=1C=C2C=C(N(C2=CC=1OC)S(=O)(=O)C1=CC=CC=C1)C=O GHSTYTIZXKAYQC-UHFFFAOYSA-N 0.000 description 2
- XUKSXJWRFMTAPZ-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-bromoindole Chemical compound C1=CC2=CC(Br)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 XUKSXJWRFMTAPZ-UHFFFAOYSA-N 0.000 description 2
- BIZBWMORZPLKLE-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-chloroindole Chemical compound C1=CC2=CC(Cl)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 BIZBWMORZPLKLE-UHFFFAOYSA-N 0.000 description 2
- QVIFQMIUDPKYEF-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-fluoroindole Chemical compound C1=CC2=CC(F)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 QVIFQMIUDPKYEF-UHFFFAOYSA-N 0.000 description 2
- CWJDHIWTXPOWQE-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-fluoroindole-2-carbaldehyde Chemical compound FC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C=O CWJDHIWTXPOWQE-UHFFFAOYSA-N 0.000 description 2
- SBHMGZUQCCZBKQ-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-methoxypyrrolo[2,3-c]pyridine Chemical compound C1=2C=NC(OC)=CC=2C=CN1S(=O)(=O)C1=CC=CC=C1 SBHMGZUQCCZBKQ-UHFFFAOYSA-N 0.000 description 2
- JLSYIEKUHAJXKE-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-phenylmethoxyindole Chemical compound C1=CC2=CC(OCC=3C=CC=CC=3)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 JLSYIEKUHAJXKE-UHFFFAOYSA-N 0.000 description 2
- DNFDYQYKLXTYIM-UHFFFAOYSA-N 1-(benzenesulfonyl)-7-methoxyindole-2-carbaldehyde Chemical compound COC=1C=CC=C2C=C(N(C=12)S(=O)(=O)C1=CC=CC=C1)C=O DNFDYQYKLXTYIM-UHFFFAOYSA-N 0.000 description 2
- BWMBNSDNCTUEGV-UHFFFAOYSA-N 1-(benzenesulfonyl)indazole-5-carbaldehyde Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1N=CC2=CC(=CC=C12)C=O BWMBNSDNCTUEGV-UHFFFAOYSA-N 0.000 description 2
- SGUAULNPHXKBPM-UHFFFAOYSA-N 1-(benzenesulfonyl)pyrrolo[2,3-b]pyridine-5-carbaldehyde Chemical compound C1=CC2=CC(C=O)=CN=C2N1S(=O)(=O)C1=CC=CC=C1 SGUAULNPHXKBPM-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- LRAPIYDMRBZJFS-UHFFFAOYSA-N 1-benzofuran-2-yl(1H-indol-5-yl)methanone Chemical compound O1C(=CC2=C1C=CC=C2)C(=O)C=1C=C2C=CNC2=CC=1 LRAPIYDMRBZJFS-UHFFFAOYSA-N 0.000 description 2
- ANTCBCITZKPYOE-UHFFFAOYSA-N 1-benzofuran-2-yl(1h-indol-5-yl)methanol Chemical compound C1=C2NC=CC2=CC(C(C=2OC3=CC=CC=C3C=2)O)=C1 ANTCBCITZKPYOE-UHFFFAOYSA-N 0.000 description 2
- OHCKMAWCKCXKHN-UHFFFAOYSA-N 1-benzofuran-2-yl-(1-methylindol-5-yl)methanol Chemical compound O1C(=CC2=C1C=CC=C2)C(O)C=1C=C2C=CN(C2=CC=1)C OHCKMAWCKCXKHN-UHFFFAOYSA-N 0.000 description 2
- KOOINWFFBRLCHN-UHFFFAOYSA-N 1-benzofuran-2-yl-(1-methylindol-5-yl)methanone Chemical compound O1C(=CC2=C1C=CC=C2)C(=O)C=1C=C2C=CN(C2=CC=1)C KOOINWFFBRLCHN-UHFFFAOYSA-N 0.000 description 2
- NQPRHYHMHCCSJJ-UHFFFAOYSA-N 1-benzofuran-5-yl-(5-methoxy-1H-indol-2-yl)methanone Chemical compound O1C=CC2=C1C=CC(=C2)C(=O)C=1NC2=CC=C(C=C2C=1)OC NQPRHYHMHCCSJJ-UHFFFAOYSA-N 0.000 description 2
- XYAUMVPYYAPPKL-UHFFFAOYSA-N 1H-indol-5-yl(1H-pyrrolo[2,3-b]pyridin-2-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C1=CC=2C(=NC=CC=2)N1 XYAUMVPYYAPPKL-UHFFFAOYSA-N 0.000 description 2
- UUDFJHFLZBRKFU-UHFFFAOYSA-N 1H-indol-5-yl-(5-methoxy-3-methyl-1H-indol-2-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C=1NC2=CC=C(C=C2C=1C)OC UUDFJHFLZBRKFU-UHFFFAOYSA-N 0.000 description 2
- UTYPYSANNCAJKS-UHFFFAOYSA-N 1H-indol-5-yl-(5-morpholin-4-yl-1H-indol-2-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C=1NC2=CC=C(C=C2C=1)N1CCOCC1 UTYPYSANNCAJKS-UHFFFAOYSA-N 0.000 description 2
- YJKMYHNMBGQQQZ-UHFFFAOYSA-N 1h-indazole-5-carbaldehyde Chemical compound O=CC1=CC=C2NN=CC2=C1 YJKMYHNMBGQQQZ-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- HDANOCTXZFZIHB-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-5-carbaldehyde Chemical compound O=CC1=CN=C2NC=CC2=C1 HDANOCTXZFZIHB-UHFFFAOYSA-N 0.000 description 2
- WGPOFPNZWCMEGG-UHFFFAOYSA-N 2-(trifluoromethyl)-3h-benzimidazole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC(C(F)(F)F)=NC2=C1 WGPOFPNZWCMEGG-UHFFFAOYSA-N 0.000 description 2
- BTZANWCDWCODRW-UHFFFAOYSA-N 2H-benzotriazol-5-yl-(5-methoxy-1H-indol-2-yl)methanone Chemical compound N1N=NC2=C1C=CC(=C2)C(=O)C=1NC2=CC=C(C=C2C=1)OC BTZANWCDWCODRW-UHFFFAOYSA-N 0.000 description 2
- XDDIHYVTQWYYND-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-1H-indole-5-carbaldehyde Chemical compound CN(C)CC1=CNC2=CC=C(C=C12)C=O XDDIHYVTQWYYND-UHFFFAOYSA-N 0.000 description 2
- VHVCRLVEBSGUEZ-UHFFFAOYSA-N 3-chloro-1h-indole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2C(Cl)=CNC2=C1 VHVCRLVEBSGUEZ-UHFFFAOYSA-N 0.000 description 2
- PQBPTICJDNOFJF-UHFFFAOYSA-N 3-chloro-2h-indazole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2C(Cl)=NNC2=C1 PQBPTICJDNOFJF-UHFFFAOYSA-N 0.000 description 2
- CGIDHVRKIVCYLS-UHFFFAOYSA-N 3-fluoro-2H-indazole-5-carbaldehyde Chemical compound FC1=NNC2=CC=C(C=C12)C=O CGIDHVRKIVCYLS-UHFFFAOYSA-N 0.000 description 2
- SDFTVVRLUIUGNC-UHFFFAOYSA-N 3-methyl-1h-indole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2C(C)=CNC2=C1 SDFTVVRLUIUGNC-UHFFFAOYSA-N 0.000 description 2
- FGBHCSVATHXMLX-UHFFFAOYSA-N 3-methyl-2h-indazole-5-carbaldehyde Chemical compound C1=C(C=O)C=C2C(C)=NNC2=C1 FGBHCSVATHXMLX-UHFFFAOYSA-N 0.000 description 2
- YYQVROCJCWSGJO-UHFFFAOYSA-N 4-[1-(benzenesulfonyl)indol-5-yl]morpholine Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C=CC2=CC(=CC=C12)N1CCOCC1 YYQVROCJCWSGJO-UHFFFAOYSA-N 0.000 description 2
- HLCWRXQPKCRFAN-UHFFFAOYSA-N 5,6-dimethoxy-1h-indole-2-carbaldehyde Chemical compound C1=C(OC)C(OC)=CC2=C1NC(C=O)=C2 HLCWRXQPKCRFAN-UHFFFAOYSA-N 0.000 description 2
- SBOITLSQLQGSLO-UHFFFAOYSA-N 5-bromo-1-methylindole Chemical compound BrC1=CC=C2N(C)C=CC2=C1 SBOITLSQLQGSLO-UHFFFAOYSA-N 0.000 description 2
- ULRBCMBSTWUHPK-UHFFFAOYSA-N 5-bromo-3-ethyl-2h-indazole Chemical compound C1=CC(Br)=CC2=C(CC)NN=C21 ULRBCMBSTWUHPK-UHFFFAOYSA-N 0.000 description 2
- CCNJNELOBGXDFD-UHFFFAOYSA-N 5-methoxy-1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC(OC)=CC2=C1NC=C2 CCNJNELOBGXDFD-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DXKGXBUFLKANKQ-UHFFFAOYSA-N N1C=CC2=CC(=CC=C12)C(=NO)C=1NC2=CC=C(C=C2C=1)OC Chemical compound N1C=CC2=CC(=CC=C12)C(=NO)C=1NC2=CC=C(C=C2C=1)OC DXKGXBUFLKANKQ-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- OHRQZQWZYYVWTP-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound COC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C OHRQZQWZYYVWTP-UHFFFAOYSA-N 0.000 description 2
- RFMUZTDNNPSHHS-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C RFMUZTDNNPSHHS-UHFFFAOYSA-N 0.000 description 2
- VNTJKDYTOLOWPK-UHFFFAOYSA-N [1-(benzenesulfonyl)-5,6-dimethoxyindol-2-yl]-(1H-indol-5-yl)methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1OC)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CNC2=CC=1 VNTJKDYTOLOWPK-UHFFFAOYSA-N 0.000 description 2
- IOXAQXMUUQSTMI-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-chloroindol-2-yl]-[1-(benzenesulfonyl)indol-5-yl]methanol Chemical compound ClC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 IOXAQXMUUQSTMI-UHFFFAOYSA-N 0.000 description 2
- GXAOTAKMANBQCI-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-fluoroindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound FC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C GXAOTAKMANBQCI-UHFFFAOYSA-N 0.000 description 2
- QKCWXPSLXJQGKF-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-fluoroindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound FC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C QKCWXPSLXJQGKF-UHFFFAOYSA-N 0.000 description 2
- FHMDZVCPZSWZRI-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxy-3-methylindol-2-yl]-[1-(benzenesulfonyl)-3-methylindol-5-yl]methanone Chemical compound COC=1C=C2C(=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C)C FHMDZVCPZSWZRI-UHFFFAOYSA-N 0.000 description 2
- DCBZFNLAZIQKRC-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(1-benzofuran-5-yl)methanol Chemical compound O1C=CC2=C1C=CC(=C2)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 DCBZFNLAZIQKRC-UHFFFAOYSA-N 0.000 description 2
- BQYGANWODYSOGT-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(1-benzofuran-5-yl)methanone Chemical compound O1C=CC2=C1C=CC(=C2)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 BQYGANWODYSOGT-UHFFFAOYSA-N 0.000 description 2
- MCYBLJOSMWTHNW-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(1-methylindol-5-yl)methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CN(C2=CC=1)C MCYBLJOSMWTHNW-UHFFFAOYSA-N 0.000 description 2
- RUXSYXVTIPJDFW-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(2H-benzotriazol-5-yl)methanol Chemical compound N1N=NC2=C1C=CC(=C2)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 RUXSYXVTIPJDFW-UHFFFAOYSA-N 0.000 description 2
- WDQKHBBVSNZADS-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(3-ethyl-2H-indazol-5-yl)methanol Chemical compound C(C)C1=NNC2=CC=C(C=C12)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 WDQKHBBVSNZADS-UHFFFAOYSA-N 0.000 description 2
- DTGUFBXPPSBXKQ-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(3-ethyl-2H-indazol-5-yl)methanone Chemical compound C(C)C1=NNC2=CC=C(C=C12)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 DTGUFBXPPSBXKQ-UHFFFAOYSA-N 0.000 description 2
- RFFCKQOPMPEWOH-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C RFFCKQOPMPEWOH-UHFFFAOYSA-N 0.000 description 2
- JYLLMXQBGDAVSK-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C JYLLMXQBGDAVSK-UHFFFAOYSA-N 0.000 description 2
- NBDXZTKWCWGNEK-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)-3-methylindol-5-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C NBDXZTKWCWGNEK-UHFFFAOYSA-N 0.000 description 2
- HOTVGRAIONBUOA-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-5-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NC=1)N(C=C2)S(=O)(=O)C1=CC=CC=C1 HOTVGRAIONBUOA-UHFFFAOYSA-N 0.000 description 2
- BQVNOUKBSBYQPX-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-5-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NC=1)N(C=C2)S(=O)(=O)C1=CC=CC=C1 BQVNOUKBSBYQPX-UHFFFAOYSA-N 0.000 description 2
- YPWKYBKEYBIWKV-UHFFFAOYSA-N [1-(benzenesulfonyl)-7-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound COC=1C=CC=C2C=C(N(C=12)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C YPWKYBKEYBIWKV-UHFFFAOYSA-N 0.000 description 2
- BIYLAFYOIDHFKS-UHFFFAOYSA-N [1-(benzenesulfonyl)-7-methoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound COC=1C=CC=C2C=C(N(C=12)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C BIYLAFYOIDHFKS-UHFFFAOYSA-N 0.000 description 2
- VVIWZZZAOSRLQZ-UHFFFAOYSA-N [1-(benzenesulfonyl)indazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=NN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 VVIWZZZAOSRLQZ-UHFFFAOYSA-N 0.000 description 2
- FNFJKZZYZNQOFB-UHFFFAOYSA-N [1-(benzenesulfonyl)indazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=NN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 FNFJKZZYZNQOFB-UHFFFAOYSA-N 0.000 description 2
- SQLNTFINYJMCSZ-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-methoxy-3-methylindol-2-yl]methanol Chemical compound COC=1C=C2C(=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C SQLNTFINYJMCSZ-UHFFFAOYSA-N 0.000 description 2
- QACCTNRHAGTPHK-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-methoxy-3-methylindol-2-yl]methanone Chemical compound COC=1C=C2C(=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C QACCTNRHAGTPHK-UHFFFAOYSA-N 0.000 description 2
- GYDVOZQESUCSRJ-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 GYDVOZQESUCSRJ-UHFFFAOYSA-N 0.000 description 2
- DHPLKEFUDOTZAC-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 DHPLKEFUDOTZAC-UHFFFAOYSA-N 0.000 description 2
- JMPQRUJAKJUAAG-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-morpholin-4-ylindol-2-yl]methanol Chemical compound O1CCN(CC1)C=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 JMPQRUJAKJUAAG-UHFFFAOYSA-N 0.000 description 2
- SJOJYBKQSHBWTH-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-5-yl]-[1-(benzenesulfonyl)-5-morpholin-4-ylindol-2-yl]methanone Chemical compound O1CCN(CC1)C=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 SJOJYBKQSHBWTH-UHFFFAOYSA-N 0.000 description 2
- ULSNAKQCGYAQPS-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-6-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C1=CC=C2C=CN(C2=C1)S(=O)(=O)C1=CC=CC=C1 ULSNAKQCGYAQPS-UHFFFAOYSA-N 0.000 description 2
- LFBHNEHQNQPAQW-UHFFFAOYSA-N [1-(benzenesulfonyl)indol-6-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C1=CC=C2C=CN(C2=C1)S(=O)(=O)C1=CC=CC=C1 LFBHNEHQNQPAQW-UHFFFAOYSA-N 0.000 description 2
- FWZDRHJRVSZFHF-UHFFFAOYSA-N [3-[(dimethylamino)methyl]-1H-indol-5-yl]-(5-methoxy-1H-indol-2-yl)methanone Chemical compound CN(C)CC1=CNC2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC FWZDRHJRVSZFHF-UHFFFAOYSA-N 0.000 description 2
- HWLGYPTYFYENTO-UHFFFAOYSA-N [5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]-(3-methyl-1H-indol-5-yl)methanone hydrochloride Chemical compound Cl.CN(C)CCOc1ccc2[nH]c(cc2c1)C(=O)c1ccc2[nH]cc(C)c2c1 HWLGYPTYFYENTO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000004705 aldimines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- BGTDPWDQIVMDGC-UHFFFAOYSA-N azanium;fluoride;trihydrate Chemical compound [NH4+].O.O.O.[F-] BGTDPWDQIVMDGC-UHFFFAOYSA-N 0.000 description 2
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical group N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005067 haloformyl group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- UTWGRMYWDUMKNY-UHFFFAOYSA-N indole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)C=CC2=C1 UTWGRMYWDUMKNY-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- NFOKCUQWYHRJGR-UHFFFAOYSA-N phosphonosulfanylphosphonic acid Chemical compound OP(O)(=O)SP(O)(O)=O NFOKCUQWYHRJGR-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- UFRSNLKGVNZDLB-UHFFFAOYSA-N tert-butyl 3-[(dimethylamino)methyl]-5-(5-methoxy-1H-indole-2-carbonyl)indole-1-carboxylate Chemical compound CN(C)CC1=CN(C2=CC=C(C=C12)C(=O)C=1NC2=CC=C(C=C2C=1)OC)C(=O)OC(C)(C)C UFRSNLKGVNZDLB-UHFFFAOYSA-N 0.000 description 2
- XJBYJZZSAHIBAB-UHFFFAOYSA-N tert-butyl 3-[(dimethylamino)methyl]-5-[hydroxy-(5-methoxy-1H-indol-2-yl)methyl]indole-1-carboxylate Chemical compound CN(C)CC1=CN(C2=CC=C(C=C12)C(C=1NC2=CC=C(C=C2C=1)OC)O)C(=O)OC(C)(C)C XJBYJZZSAHIBAB-UHFFFAOYSA-N 0.000 description 2
- WVTVWJCCYKSQJN-UHFFFAOYSA-N tert-butyl 3-[(dimethylamino)methyl]-5-formylindole-1-carboxylate Chemical compound CN(C)CC1=CN(C2=CC=C(C=C12)C=O)C(=O)OC(C)(C)C WVTVWJCCYKSQJN-UHFFFAOYSA-N 0.000 description 2
- FUXCWKLHNRRBJG-UHFFFAOYSA-N tert-butyl 5-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridine-2-carbonyl]indole-1-carboxylate Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C(=CC=2C1=NC=CC=2)C(=O)C=1C=C2C=CN(C2=CC=1)C(=O)OC(C)(C)C FUXCWKLHNRRBJG-UHFFFAOYSA-N 0.000 description 2
- TXCKPZOWRGLPMU-UHFFFAOYSA-N tert-butyl 5-[[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-2-yl]-hydroxymethyl]indole-1-carboxylate Chemical compound OC(C=1C=C2C=CN(C2=CC=1)C(=O)OC(C)(C)C)C1=CC=2C(=NC=CC=2)N1S(=O)(=O)C1=CC=CC=C1 TXCKPZOWRGLPMU-UHFFFAOYSA-N 0.000 description 2
- KDMYWOVAHWERQN-UHFFFAOYSA-N tert-butyl 5-formylindole-1-carboxylate Chemical compound O=CC1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1 KDMYWOVAHWERQN-UHFFFAOYSA-N 0.000 description 2
- JDDPITNKUXPLSB-UHFFFAOYSA-N tert-butyl morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1 JDDPITNKUXPLSB-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ZUBHEDOIBQETHF-UHFFFAOYSA-N (2-methyl-3h-benzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2NC(C)=NC2=C1 ZUBHEDOIBQETHF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FSWKXTDJERSMKD-UHFFFAOYSA-N (5-chloro-1H-indol-2-yl)-(1H-indol-5-yl)methanone Chemical compound ClC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C=CNC2=CC=1 FSWKXTDJERSMKD-UHFFFAOYSA-N 0.000 description 1
- FGMMENOWVLTEFA-UHFFFAOYSA-N (5-hydroxy-1H-indol-2-yl)-(1H-indol-5-yl)methanone Chemical compound OC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C=CNC2=CC=1 FGMMENOWVLTEFA-UHFFFAOYSA-N 0.000 description 1
- CUKRDQFDEWMSKY-UHFFFAOYSA-N (5-methoxy-1-methylindol-2-yl)-(1-methylindol-5-yl)methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)C)C(=O)C=1C=C2C=CN(C2=CC=1)C CUKRDQFDEWMSKY-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- BBMSCWQKJDTWGK-UHFFFAOYSA-N 1-(5-bromo-2-fluorophenyl)propan-1-ol Chemical compound CCC(O)C1=CC(Br)=CC=C1F BBMSCWQKJDTWGK-UHFFFAOYSA-N 0.000 description 1
- JPLYCGNNGYBEQO-UHFFFAOYSA-N 1-(benzenesulfonyl)-7-methoxyindole Chemical compound C1=2C(OC)=CC=CC=2C=CN1S(=O)(=O)C1=CC=CC=C1 JPLYCGNNGYBEQO-UHFFFAOYSA-N 0.000 description 1
- XWVXMNKMVDFYMO-UHFFFAOYSA-N 1-(benzenesulfonyl)indole-6-carbaldehyde Chemical compound C12=CC(C=O)=CC=C2C=CN1S(=O)(=O)C1=CC=CC=C1 XWVXMNKMVDFYMO-UHFFFAOYSA-N 0.000 description 1
- LLLBDLDNTMMZHL-UHFFFAOYSA-N 1-benzofuran-5-carbaldehyde Chemical compound O=CC1=CC=C2OC=CC2=C1 LLLBDLDNTMMZHL-UHFFFAOYSA-N 0.000 description 1
- XIVDZBIBWGQOTI-UHFFFAOYSA-N 1-methylindole-5-carbaldehyde Chemical compound O=CC1=CC=C2N(C)C=CC2=C1 XIVDZBIBWGQOTI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DZZMHLRCGLBGPY-UHFFFAOYSA-N 1H-indol-5-yl-(5-methoxy-1H-indol-3-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C1=CNC2=CC=C(C=C12)OC DZZMHLRCGLBGPY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DJNQRLCFAHKFLZ-UHFFFAOYSA-N 2-methoxy-4-methyl-5-nitropyridine Chemical compound COC1=CC(C)=C([N+]([O-])=O)C=N1 DJNQRLCFAHKFLZ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LUNOXNMCFPFPMO-UHFFFAOYSA-N 4-methoxy-1h-indole Chemical compound COC1=CC=CC2=C1C=CN2 LUNOXNMCFPFPMO-UHFFFAOYSA-N 0.000 description 1
- LJFVSIDBFJPKLD-UHFFFAOYSA-N 4-phenylmethoxy-1h-indole Chemical compound C=1C=CC=2NC=CC=2C=1OCC1=CC=CC=C1 LJFVSIDBFJPKLD-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 1
- LPTVWZSQAIDCEB-UHFFFAOYSA-N 5-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CN=C2NC=CC2=C1 LPTVWZSQAIDCEB-UHFFFAOYSA-N 0.000 description 1
- BQCIJWPKDPZNHD-UHFFFAOYSA-N 5-bromo-2h-benzotriazole Chemical compound C1=C(Br)C=CC2=NNN=C21 BQCIJWPKDPZNHD-UHFFFAOYSA-N 0.000 description 1
- GDQXDVJFMLNXHX-UHFFFAOYSA-N 5-bromo-3-methyl-1h-indole Chemical compound C1=C(Br)C=C2C(C)=CNC2=C1 GDQXDVJFMLNXHX-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- JCQLPDZCNSVBMS-UHFFFAOYSA-N 5-phenylmethoxy-1h-indole Chemical compound C=1C=C2NC=CC2=CC=1OCC1=CC=CC=C1 JCQLPDZCNSVBMS-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FHDFUQGJYYGLHJ-UHFFFAOYSA-N 6-bromo-2-methyl-1h-benzimidazole Chemical compound C1=C(Br)C=C2NC(C)=NC2=C1 FHDFUQGJYYGLHJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- FSOPPXYMWZOKRM-UHFFFAOYSA-N 7-methoxy-1h-indole Chemical compound COC1=CC=CC2=C1NC=C2 FSOPPXYMWZOKRM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NJZAYPSTNXXEOF-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)N1N=C(C2=CC=CC=C12)C Chemical compound C(C1=CC=CC=C1)OC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)N1N=C(C2=CC=CC=C12)C NJZAYPSTNXXEOF-UHFFFAOYSA-N 0.000 description 1
- PLVGWTKGWUPMMW-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C=C2C=C(N(C2=CC1)S(=O)(=O)C1=CC=CC=C1)N1N=C(C2=CC=CC=C12)C Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=C(N(C2=CC1)S(=O)(=O)C1=CC=CC=C1)N1N=C(C2=CC=CC=C12)C PLVGWTKGWUPMMW-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- YXUOPDIPBGTKHL-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-chloroindazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound ClC1=NN(C2=CC=C(C=C12)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 YXUOPDIPBGTKHL-UHFFFAOYSA-N 0.000 description 1
- KSPIBWCFGRHDKV-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-chloroindazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound ClC1=NN(C2=CC=C(C=C12)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 KSPIBWCFGRHDKV-UHFFFAOYSA-N 0.000 description 1
- LSOUIKVSKALTOA-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-chloroindol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound ClC1=CN(C2=CC=C(C=C12)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 LSOUIKVSKALTOA-UHFFFAOYSA-N 0.000 description 1
- XQWJPWQASUAJLU-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-fluoroindazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanol Chemical compound FC1=NN(C2=CC=C(C=C12)C(O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 XQWJPWQASUAJLU-UHFFFAOYSA-N 0.000 description 1
- WOEFNTRSIREMFK-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-fluoroindazol-5-yl]-[1-(benzenesulfonyl)-5-methoxyindol-2-yl]methanone Chemical compound FC1=NN(C2=CC=C(C=C12)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)S(=O)(=O)C1=CC=CC=C1 WOEFNTRSIREMFK-UHFFFAOYSA-N 0.000 description 1
- UVGCUHFQUJIUQH-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-chloro-5-methoxyindol-2-yl]-(1H-indazol-5-yl)methanol Chemical compound ClC1=C2C=C(N(C2=CC=C1OC)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=NNC2=CC=1 UVGCUHFQUJIUQH-UHFFFAOYSA-N 0.000 description 1
- MISUPAPCZVLIIT-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-chloro-5-methoxyindol-2-yl]-(1H-indazol-5-yl)methanone Chemical compound ClC1=C2C=C(N(C2=CC=C1OC)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=NNC2=CC=1 MISUPAPCZVLIIT-UHFFFAOYSA-N 0.000 description 1
- ZBGDJJJGSHIQFL-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-phenylmethoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound C(C1=CC=CC=C1)OC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C ZBGDJJJGSHIQFL-UHFFFAOYSA-N 0.000 description 1
- LOAXMKBTNMSAKP-UHFFFAOYSA-N [1-(benzenesulfonyl)-4-phenylmethoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound C(C1=CC=CC=C1)OC1=C2C=C(N(C2=CC=C1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C LOAXMKBTNMSAKP-UHFFFAOYSA-N 0.000 description 1
- CFCKJXKMQBQMFS-UHFFFAOYSA-N [1-(benzenesulfonyl)-5,6-dimethoxyindol-2-yl]-(1H-indol-5-yl)methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1OC)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C=CNC2=CC=1 CFCKJXKMQBQMFS-UHFFFAOYSA-N 0.000 description 1
- JPVKBUGWFDCHOT-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-chloroindol-2-yl]-[1-(benzenesulfonyl)indol-5-yl]methanone Chemical compound ClC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1 JPVKBUGWFDCHOT-UHFFFAOYSA-N 0.000 description 1
- PKTQDJJGCFSPRT-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxy-3-methylindol-2-yl]-[1-(benzenesulfonyl)-3-methylindol-5-yl]methanol Chemical compound COC=1C=C2C(=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C)C PKTQDJJGCFSPRT-UHFFFAOYSA-N 0.000 description 1
- VFNINYMEASIFKL-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(2-methyl-3H-benzimidazol-5-yl)methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C1=CC2=C(NC(=N2)C)C=C1 VFNINYMEASIFKL-UHFFFAOYSA-N 0.000 description 1
- SAZDDOOPBPCQPY-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-(2H-benzotriazol-5-yl)methanone Chemical compound N1N=NC2=C1C=CC(=C2)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1 SAZDDOOPBPCQPY-UHFFFAOYSA-N 0.000 description 1
- YNGUUWACJKWMNA-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)-2-(trifluoromethyl)benzimidazol-5-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C1=CC2=C(N(C(=N2)C(F)(F)F)S(=O)(=O)C2=CC=CC=C2)C=C1 YNGUUWACJKWMNA-UHFFFAOYSA-N 0.000 description 1
- KQHNJOHXFXJIIQ-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)-2-(trifluoromethyl)benzimidazol-5-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C1=CC2=C(N(C(=N2)C(F)(F)F)S(=O)(=O)C2=CC=CC=C2)C=C1 KQHNJOHXFXJIIQ-UHFFFAOYSA-N 0.000 description 1
- ASERDNHVZSNHGP-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[1-(benzenesulfonyl)-3-methylindol-5-yl]methanol Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=CN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C ASERDNHVZSNHGP-UHFFFAOYSA-N 0.000 description 1
- NKUQJZHDXLVGRO-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxyindol-2-yl]-[3-(morpholin-4-ylmethyl)-2H-indazol-5-yl]methanone Chemical compound COC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)CN1CCOCC1 NKUQJZHDXLVGRO-UHFFFAOYSA-N 0.000 description 1
- QYKPEYZSQGWZFX-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxypyrrolo[2,3-c]pyridin-2-yl]-[1-(benzenesulfonyl)-3-methylindazol-5-yl]methanol Chemical compound COC=1C=C2C(=CN=1)N(C(=C2)C(O)C=1C=C2C(=NN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C)S(=O)(=O)C1=CC=CC=C1 QYKPEYZSQGWZFX-UHFFFAOYSA-N 0.000 description 1
- BAMSQDXKNDNMIE-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-methoxypyrrolo[2,3-c]pyridin-2-yl]-[1-(benzenesulfonyl)-3-methylindazol-5-yl]methanone Chemical compound COC=1C=C2C(=CN=1)N(C(=C2)C(=O)C=1C=C2C(=NN(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C)S(=O)(=O)C1=CC=CC=C1 BAMSQDXKNDNMIE-UHFFFAOYSA-N 0.000 description 1
- AGTXEXKZTHATBB-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-phenylmethoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(O)C=1C=C2C(=NNC2=CC=1)C AGTXEXKZTHATBB-UHFFFAOYSA-N 0.000 description 1
- QJJKDUJXDYUSFM-UHFFFAOYSA-N [1-(benzenesulfonyl)-5-phenylmethoxyindol-2-yl]-(3-methyl-2H-indazol-5-yl)methanone Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=C(N(C2=CC=1)S(=O)(=O)C1=CC=CC=C1)C(=O)C=1C=C2C(=NNC2=CC=1)C QJJKDUJXDYUSFM-UHFFFAOYSA-N 0.000 description 1
- RSXHVDDZCNSYPD-UHFFFAOYSA-N [1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-2-yl]-(1H-indol-5-yl)methanone Chemical compound N1C=CC2=CC(=CC=C12)C(=O)C1=CC=2C(=NC=CC=2)N1S(=O)(=O)C1=CC=CC=C1 RSXHVDDZCNSYPD-UHFFFAOYSA-N 0.000 description 1
- SEIKEUBNZVQKHL-UHFFFAOYSA-N [2-(trifluoromethyl)-3h-benzimidazol-5-yl]methanol Chemical compound OCC1=CC=C2N=C(C(F)(F)F)NC2=C1 SEIKEUBNZVQKHL-UHFFFAOYSA-N 0.000 description 1
- PAMNKLBCNYISMM-UHFFFAOYSA-N [5-[2-(dimethylamino)ethoxy]-1H-indol-2-yl]-(3-methyl-1H-indol-5-yl)methanone Chemical compound CN(CCOC=1C=C2C=C(NC2=CC=1)C(=O)C=1C=C2C(=CNC2=CC=1)C)C PAMNKLBCNYISMM-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000011291 current first-line treatment Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- WOQXCSGTWFKUSU-UHFFFAOYSA-N ethyl 2-(trifluoromethyl)-3h-benzimidazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=C(C(F)(F)F)NC2=C1 WOQXCSGTWFKUSU-UHFFFAOYSA-N 0.000 description 1
- RBUSDPZPBBBAKR-UHFFFAOYSA-N ethyl 5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC1=C(OC)C=C2NC(C(=O)OCC)=CC2=C1 RBUSDPZPBBBAKR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000005155 haloalkylene group Chemical group 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- HLVSZSQYBQCBQG-UHFFFAOYSA-N indolo[3,2-b]carbazole Chemical class C12=CC=CC=C2N=C2C1=CC1=NC3=CC=CC=C3C1=C2 HLVSZSQYBQCBQG-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- PHZVAKSKMBVEHM-UHFFFAOYSA-N methyl 2-(trifluoromethyl)-3h-benzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N=C(C(F)(F)F)NC2=C1 PHZVAKSKMBVEHM-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- SMURSSZMVCOKOO-UHFFFAOYSA-N tert-butyl 3-methylindole-1-carboxylate Chemical compound C1=CC=C2C(C)=CN(C(=O)OC(C)(C)C)C2=C1 SMURSSZMVCOKOO-UHFFFAOYSA-N 0.000 description 1
- GMYSOTMFKZMFSD-UHFFFAOYSA-N tert-butyl 5-[1-(benzenesulfonyl)-5-methoxyindole-2-carbonyl]-3-[(dimethylamino)methyl]indole-1-carboxylate Chemical compound CN(C)CC1=CN(C2=CC=C(C=C12)C(=O)C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)C(=O)OC(C)(C)C GMYSOTMFKZMFSD-UHFFFAOYSA-N 0.000 description 1
- VBHZLCLWHGDYFL-UHFFFAOYSA-N tert-butyl 5-[[1-(benzenesulfonyl)-5-methoxyindol-2-yl]-hydroxymethyl]-3-[(dimethylamino)methyl]indole-1-carboxylate Chemical compound CN(C)CC1=CN(C2=CC=C(C=C12)C(C=1N(C2=CC=C(C=C2C=1)OC)S(=O)(=O)C1=CC=CC=C1)O)C(=O)OC(C)(C)C VBHZLCLWHGDYFL-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Description
本発明は腫瘍細胞増殖のような状態の治療、癌の治療および転移の抑制のための方法および組成物を提供する。
XはOまたはNOHである;
各R’は、独立して、置換または非置換アミン(NH、NMe)またはOである;
各R’’は、独立して、NまたはCRである;および
各Rは、独立して、H、ハロ、OH、またはC1−C9アルキル、アルキルアミンもしくはアルキルエーテルであり、その各々は置換体または非置換体であり、0〜3個のヘテロ原子を含む]の化合物、またはその医薬上許容される塩、ヒドリドもしくは立体異性体である。
R1〜R5およびR10は、独立して、H、ハロ、OH、またはC1−C9アルキル、アルキルアミンもしくはアルキルエーテルであり、その各々は置換体または非置換体であり、N、O、SおよびPから選択される0〜3個のヘテロ原子を含む;
R6〜R7は、独立して、NまたはCR10である;ならびに
R8〜R9は、独立して、HまたはMeである;
の1つ、2つまたは3つを満たす、式II:
R1、R2、R4およびR5はHである;
R3はOH、またはC1−C6もしくはアルキルエーテルであり、これは置換体または非置換体であり、N、O、SおよびPから選択される0〜3個のヘテロ原子を含む;
R7はCR10である;ならびに
R8およびR9はHである;
の1つ、2つ、3つまたは4つを満たす化合物、またはその医薬上許容される塩、ヒドリドもしくは立体異性体である。
特定の実施形態および実施例の以下の説明は限定的なものではなく例示として記載されている。当業者は、実質的に類似した結果を得るために変更または修飾されうる種々の非臨界パラメータを容易に認識するであろう。本発明は多種多様な実施形態を提供する。
本発明者らは、強力なインビトロおよびインビボ抗癌活性を有する、経口活性であり非常に有効かつ選択的なMAP4K4インヒビターを成功裏に開発した。例示されているインヒビターは、試験された乳癌細胞系のほとんどに対してパクリタキセル(タキソール)より強力であり、トリプルネガティブ体(MDA−MB−231、BT549およびHs578T細胞)に対して、エストロゲン依存性(T47DおよびMCF−7)乳癌細胞系に対する場合より強力な活性を示す。一般に、それらの効力は癌細胞系におけるMAP4K4発現と正に相関する。
(3−クロロ−1H−インドール−5−イル)(3,4−ジクロロ−5−メトキシ−1H−インドール−2−イル)メタノンおよび(3−クロロ−1H−インドール−5−イル)(3−クロロ−5−メトキシ−1H−インドール−2−イル)メタノン
Claims (9)
- 以下の条件、すなわち、
R1、R2、R4およびR5はHである;
R3はOH、またはC1−C6もしくはアルキルエーテルであり、これは置換体または非置換体であり、N、O、SおよびPから選択される0〜3個のヘテロ原子を含む;
R7はCR10である;ならびに
R8およびR9はHである;
の1つ、2つ、3つまたは4つを満たす、請求項1記載の化合物、またはその医薬上許容される塩、ヒドリドもしくは立体異性体。 - ジインドリルメタノンまたはインドール−2−イル、インドール−6−イル−メタノンである、請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体。
- 表Iの化合物である、請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体。
- 請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体を単位投与形態中に含む、ヒトへの投与に適した医薬組成物。
- 腫瘍細胞増殖の抑制、癌の治療または転移の抑制のための第2の異なる医薬と共にパッケージングまたは製剤化された、請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体を含む組成物。
- 腫瘍細胞増殖の抑制、癌の治療または転移の抑制のための、請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体の、それを要する者における使用。
- 腫瘍細胞増殖、癌もしくは転移を診断する先行工程、および/または腫瘍細胞増殖、癌もしくは転移の、生じた軽減を検出する後続工程を更に含む、腫瘍細胞増殖の抑制、癌の治療または転移の抑制のための、請求項1記載の化合物またはその医薬上許容される塩、ヒドリドもしくは立体異性体の、それを要する者における使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562104764P | 2015-01-18 | 2015-01-18 | |
US62/104,764 | 2015-01-18 | ||
PCT/US2015/036816 WO2016114816A1 (en) | 2015-01-18 | 2015-06-19 | MAP4K4 (HGK) Inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018502138A true JP2018502138A (ja) | 2018-01-25 |
JP6820854B2 JP6820854B2 (ja) | 2021-01-27 |
Family
ID=56406199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017537944A Active JP6820854B2 (ja) | 2015-01-18 | 2015-06-19 | Map4k4(hgk)インヒビター |
Country Status (4)
Country | Link |
---|---|
US (1) | US10000451B2 (ja) |
EP (1) | EP3233797B1 (ja) |
JP (1) | JP6820854B2 (ja) |
WO (1) | WO2016114816A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110734390A (zh) * | 2019-11-19 | 2020-01-31 | 苏州永健生物医药有限公司 | 5-醛基吲哚的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005516895A (ja) * | 2001-10-26 | 2005-06-09 | バクスター ヘルスケア ソシエテ アノニム | 腫瘍の治療のための2−アシルインドールの使用 |
JP2006519259A (ja) * | 2003-03-03 | 2006-08-24 | アレイ バイオファーマ、インコーポレイテッド | p38阻害剤及びその使用法 |
JP2012523380A (ja) * | 2009-04-09 | 2012-10-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hiv複製の阻害薬 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA00006605A (es) * | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
AU783459B2 (en) * | 2000-04-28 | 2005-10-27 | Baxter Healthcare Sa | 2-acyl indol derivatives and their use as anti-tumour agents |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
US20090142832A1 (en) * | 2007-11-29 | 2009-06-04 | James Dalton | Indoles, Derivatives, and Analogs Thereof and Uses Therefor |
JP6363020B2 (ja) * | 2012-01-30 | 2018-07-25 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリンおよびナフチリジン誘導体 |
-
2015
- 2015-06-19 JP JP2017537944A patent/JP6820854B2/ja active Active
- 2015-06-19 WO PCT/US2015/036816 patent/WO2016114816A1/en active Application Filing
- 2015-06-19 EP EP15878248.2A patent/EP3233797B1/en active Active
-
2017
- 2017-07-15 US US15/650,902 patent/US10000451B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005516895A (ja) * | 2001-10-26 | 2005-06-09 | バクスター ヘルスケア ソシエテ アノニム | 腫瘍の治療のための2−アシルインドールの使用 |
JP2006519259A (ja) * | 2003-03-03 | 2006-08-24 | アレイ バイオファーマ、インコーポレイテッド | p38阻害剤及びその使用法 |
JP2012523380A (ja) * | 2009-04-09 | 2012-10-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hiv複製の阻害薬 |
Non-Patent Citations (5)
Title |
---|
ARZNEIM.-FORSCH./DRUG RES., vol. Vol.28(I), JPN6019005496, 1978, pages 586 - 594 * |
DATABASE REGISTRY, JPN7019000434, 2014 * |
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.87, JPN6019005498, 2014, pages 306 - 315 * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol.44, JPN6019005497, 2001, pages 4535 - 4553 * |
LEUKEMIA, vol. Vol.16, JPN6019005499, 2002, pages 1528 - 1534 * |
Also Published As
Publication number | Publication date |
---|---|
US10000451B2 (en) | 2018-06-19 |
EP3233797A1 (en) | 2017-10-25 |
JP6820854B2 (ja) | 2021-01-27 |
EP3233797A4 (en) | 2017-11-22 |
US20170320824A1 (en) | 2017-11-09 |
EP3233797B1 (en) | 2019-05-08 |
WO2016114816A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10918642B2 (en) | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | |
TWI530499B (zh) | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 | |
JP5642963B2 (ja) | ピリジノニルpdk1阻害剤 | |
JP2022137128A (ja) | Ash1l阻害剤及びそれを用いた治療方法 | |
KR20190038915A (ko) | 피리도피리미딘온 cdk2/4/6 억제제 | |
US11352354B2 (en) | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
JP2021502386A (ja) | Ash1l分解剤及びそれを用いた治療方法 | |
ES2927529T3 (es) | Compuesto heterocíclico condensado | |
EP3568397B1 (en) | Compounds and their use in the treatment of schistosomiasis | |
CN116940354A (zh) | 稠合的杂芳基化合物及其作为CaMKII抑制剂的用途 | |
CN109641909B (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
US10000451B2 (en) | MAP4K4 (HGK) inhibitors | |
JP6170260B2 (ja) | 5−ht2bアンタゴニスト | |
Zhang et al. | Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors | |
JP2021527064A (ja) | Prc1阻害剤及びそれを用いた治療方法 | |
WO2015120737A1 (zh) | 取代的吡啶并嘧啶化合物及其制备方法和应用 | |
CA2562561A1 (fr) | Derives de pyridoindolone substitues en -6, leur preparation, leur application en therapeutique. | |
CN108203433B (zh) | 一种rock抑制剂及其应用 | |
KR102655210B1 (ko) | 아데노신 a2a 수용체 길항제 및 이의 용도 | |
WO2022206583A1 (zh) | 吲唑类化合物及其制备方法和应用 | |
BR112018010473B1 (pt) | Composto, composição farmacêutica e uso do composto | |
WO2018199797A1 (ru) | Замещенные 2-метилиден-5-(фениламино)-2,3-дигидротиофен-3-оны для лечения лейкозов с транслокациями mll-гена и других онкологических заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171019 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180618 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201215 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6820854 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |